Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NNMT drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Target Enzyme | NNMT Recombinant Protein (WT & Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Ideal for HTS and structural biology. |
View NNMT Products |
| Gene Delivery | NNMT Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and metabolic flux assays. |
View NNMT Products |
| Benchmark Ab | Anti-NNMT Primary Antibody Recombinant positive control for western blot and target engagement assays. |
View NNMT Products |
| Validator | NNMT siRNA Set For specific gene knockdown verification in cell-based assays. |
View NNMT Products |
| Related Target A | NAMPT Crucial node in the NAD+ salvage pathway; synergistic metabolic target. |
View NAMPT Products |
| Related Target B | CD38 NAD+ consuming enzyme; compensatory pathway for NNMT inhibition. |
View CD38 Products |
| Related Target C | SIRT1 NAD+-dependent deacetylase directly impacted by NNMT metabolic flux. |
View SIRT1 Products |
| Related Target D | PNMT Off-target safety counter-screen; methyltransferase family selectivity. |
View PNMT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Assay Reproducibility | High Purity (>95%) recombinant protein, rigorously Sequence Verified, with tightly controlled formulation. |
| Off-Target Methyltransferase Screening | Expanded portfolio of related epigenetic targets for precise selectivity profiling. |
| Species Cross-Reactivity for Toxicology & PK | Human / Mouse / Rat / Cyno ortholog proteins available; Endotoxin controlled. |
| Intracellular Target Engagement | Lentivirus-ready constructs for generating stable overexpression cell lines. |
| False Positives in Phenotypic Screens | Sequence-validated siRNA sets included for robust genetic specificity checks. |
| Mechanistic Binding Studies | High-concentration protein compatible with SPR/ITC and thermal shift assays. |
Live NNMT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NNMT (Nicotinamide N-methyltransferase) therapeutics is gaining momentum as the industry recognizes its critical role in immunometabolism, epigenetic regulation, and cancer cell plasticity. Overexpressed in solid tumors like glioblastoma, clear cell renal cell carcinoma (ccRCC), and ovarian cancer, NNMT acts as a metabolic sink for methyl groups, depleting S-adenosylmethionine (SAM) and driving oncogenic epigenetic shifts. First-generation small molecule inhibitors are advancing toward IND-enabling studies, while the next wave of R&D targets allosteric inhibition modalities, liver-directed siRNA, and NAD+-metabolome companion biomarkers to stratify patient populations. Combination strategies with NAMPT inhibitors, immune checkpoint blockades, and NAD+ precursor supplementation are emerging to overcome metabolic compensation and immunosuppressive tumor microenvironments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Metabolic disease biotechs; NAD+ biology pioneers; AI-driven platforms | Solid Tumors (ccRCC, GBM), Obesity, NAFLD/NASH | Biochemical inhibition & selectivity panel (need high-purity WT NNMT + PNMT/CD38 homologs) |
| Small Molecule (Allosteric) | Emerging Startups | Metabolic Disorders, Fibrosis | Structural validation (need sequence-verified antigens) |
| siRNA / Antisense | Liver-targeted metabolic ventures | Obesity, Dyslipidemia, NASH, Hepatocellular Carcinoma | Cell-based knockdown + 1-MNA quantification (need lentivirus overexpression & siRNA) |
| PROTAC / Degrader | Preclinical Discovery Labs | Treatment-Resistant Solid Tumors | Ternary complex assays (need stable recombinant proteins & ligand-binding mutants) |
| Biomarker / Diagnostic | Academic medical centers | Cancer stratification, Metabolic syndrome monitoring | ELISA-grade detection antibody pairs (need high-specificity anti-NNMT antibodies) |